Defining the Role of ROR2 in Right Ventricular Failure Pathogenesis

定义 ROR2 在右心室衰竭发病机制中的作用

基本信息

项目摘要

ABSTRACT The proposal in this application outlines a five-year career development plan to prepare the candidate, Dr. Jonathan Edwards, MD, for a career as an independent physician-scientist defining mechanisms of right ventricular failure (RVF). The research and development plans are carefully structured to expand Dr. Edwards’s scientific foundation in cardiovascular research by providing technical training and expertise in in vitro cardiomyocyte biology, molecular biology, transgenic murine model development, and characterization of RV function in murine models. Dr. Edwards’s development plan will also strengthen his communication, leadership, and collaboration skills through attendance of high yield coursework, workshops, and seminars. RVF is a significant health problem that is a strong predictor of death, and for which there are no proven therapies. The lack of human or animal work investigating molecular mechanisms of RVF, which could foster the development of critically needed novel RVF therapies, is a significant gap in our field. I found that the fetal noncanonical WNT receptor ROR2 is strongly reactivated in the RV of patients with severe RVF and in mice with RVF from pressure overload. Further, this ROR2 activation was associated with upregulation of the ROR2/Ca2+ responsive protease calpain and target protein cleavage. I hypothesize that pathologic ROR2 expression is a novel and potentially targetable molecular driver of RVF and pathologic cardiomyocyte remodeling, which acts via calpain-mediated cytoskeleton and sarcomeric disruption and apoptosis in a subcellular Ca2+-dependent manner. Three interrelated, but independent Specific Aims will address this hypothesis: 1) Determine the mechanistic role for Ror2 in in vitro cardiomyocyte cytoskeleton and sarcomeric disruption and apoptosis; 2) Determine if RV-specific Ror2 overexpression is sufficient to cause RVF; and 3) Determine if RV Ror2 expression is necessary for pressure overload-induced RVF. This research training will be conducted under the mentorship of Dr. Zoltan Arany, MD, PhD (Director, Cell Biology, Physiology, and Metabolism), with co-mentorship by Dr. Benjamin Prosser, PhD (Associate Director, Penn Muscle Institute) at the University of Pennsylvania. Dr. Edwards has assembled an interdisciplinary advisory committee with expertise in in vitro cardiomyocyte biology, molecular biology, translational science, Ca2+ regulation, WNT signaling, RVF murine modeling, transgenic animal model development, and leadership. Currently he is a board-eligible pediatric cardiologist, advanced clinical fellow in pediatric cardiomyopathy, heart failure, and heart transplantation, and a postdoctoral fellow in the Arany laboratory. His long-term career goals are to serve as a physician-scientist with expertise in RV myocardial biology and the clinical management of pediatric patients with heart failure as an academic faculty member at a pediatric research hospital. Dr. Edwards will benefit from his robust and balanced mentorship team, research environment, and unequivocal divisional and institutional commitment, all of which will support his path to independence.
抽象的 该申请中的提案概述了一项为期五年的职业发展计划,以准备候选人。 医学博士乔纳森·爱德华兹(Jonathan Edwards),从事右正确的违约主义机制的职业生涯 心室失败(RVF)。 通过在体外提供技术培训和专业知识,在心血管研究中的科学基础 心肌细胞生物学,分子生物学,转基因鼠模型发展和RV的表征 爱德华兹博士的发展计划中的功能也将加强他的沟通,领导才能 以及通过参加Hield课程,研讨会和研讨会的参加协作技能。 RVF是一个重大的健康问题,是死亡的有力预测指标 疗法。 至关重要的新型RVF疗法的发展是我们领域的一个显着差距。 在患有严重RVF的患者的RV中,非经典Wnt受体ROR2强烈重新激活 RVF从压力超负荷,此ROR2激活与ROR2/Ca2+的上调有关 响应性的蛋白质裂解和靶蛋白裂解。 RVF和病理心肌细胞重塑的潜在靶向分子驱动器,可通过 钙蛋白酶介导的细胞骨架和肉瘤的破坏和凋亡依赖性Ca2+依赖性 方式。 ROR2体外心肌细胞细胞骨架的机理作用和肌肉表面的刻度观点方面 确定RV特异性的ROR2过表达是否会引起RVF; 3)确定RV ROR2是否表达 对于压力超负荷引起的RVF是必需的。 这项研究培训将在医学博士Zoltan Arany博士的指导下进行(牢房主任) 生物学,生理学和代谢),由Benjamin Prosser博士(副主任 宾夕法尼亚大学的宾夕法尼亚大学肌肉研究所。 咨询委员会具有体外心肌细胞生物学专业知识,分子生物学,转化科学, CA2+调节,WNT信号,RVF鼠建模,转基因动物模型开发和领导力。 目前,他是符合董事会资格的儿科心脏病学家,儿科心肌病的高级临床研究员,心脏 他的长期职业目标。 作为医师科学家,具有RV心肌生物学专业知识和临床管理 心力衰竭的儿科患者是作为学术教师 将从他的健壮和平衡的指导团队,研究环境和明确的分区中受益 和稳健的承诺,所有的意志都将支持他的独立之路。

项目成果

期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Temporal trends in primary payers in pediatric heart transplant and association with long-term survival.
儿科心脏移植主要支付者的时间趋势及其与长期生存的关系。
  • DOI:
    10.1111/petr.14484
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    1.3
  • 作者:
    Restaino,Kathryn;Zhang,Xuemei;Faerber,JenniferA;Rossano,JosephW;Burstein,Danielle;Wittlieb-Weber,CarolA;Lin,KimberlyYee;Edelson,JonathanB;Edwards,JonathanJ;O'Connor,MatthewJ
  • 通讯作者:
    O'Connor,MatthewJ
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Jonathan Joseph Edwards其他文献

Jonathan Joseph Edwards的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Jonathan Joseph Edwards', 18)}}的其他基金

Defining the Role of ROR2 in Right Ventricular Failure Pathogenesis
定义 ROR2 在右心室衰竭发病机制中的作用
  • 批准号:
    10463790
  • 财政年份:
    2021
  • 资助金额:
    $ 13.14万
  • 项目类别:
Defining the Role of ROR2 in Right Ventricular Failure Pathogenesis
定义 ROR2 在右心室衰竭发病机制中的作用
  • 批准号:
    10283469
  • 财政年份:
    2021
  • 资助金额:
    $ 13.14万
  • 项目类别:

相似国自然基金

Tenascin-X对急性肾损伤血管内皮细胞的保护作用及机制研究
  • 批准号:
    82300764
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
活性脂质Arlm-1介导的自噬流阻滞在儿童T细胞急性淋巴细胞白血病化疗耐药逆转中的作用机制研究
  • 批准号:
    82300182
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
PHF6突变通过相分离调控YTHDC2-m6A-SREBP2信号轴促进急性T淋巴细胞白血病发生发展的机制研究
  • 批准号:
    82370165
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
SGO2/MAD2互作调控肝祖细胞的细胞周期再进入影响急性肝衰竭肝再生的机制研究
  • 批准号:
    82300697
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
KIF5B调控隧道纳米管介导的线粒体转运对FLT3-ITD阳性急性髓系白血病的作用机制
  • 批准号:
    82370175
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目

相似海外基金

Defining the Role of ROR2 in Right Ventricular Failure Pathogenesis
定义 ROR2 在右心室衰竭发病机制中的作用
  • 批准号:
    10463790
  • 财政年份:
    2021
  • 资助金额:
    $ 13.14万
  • 项目类别:
Regulation of vascular metabolism in acute lung injury
急性肺损伤中血管代谢的调节
  • 批准号:
    10308833
  • 财政年份:
    2021
  • 资助金额:
    $ 13.14万
  • 项目类别:
Defining the Role of ROR2 in Right Ventricular Failure Pathogenesis
定义 ROR2 在右心室衰竭发病机制中的作用
  • 批准号:
    10283469
  • 财政年份:
    2021
  • 资助金额:
    $ 13.14万
  • 项目类别:
The Role of KIBRA Signaling in Podocyte Injury
KIBRA 信号传导在足细胞损伤中的作用
  • 批准号:
    10668588
  • 财政年份:
    2018
  • 资助金额:
    $ 13.14万
  • 项目类别:
The Role of KIBRA Signaling in Podocyte Injury
KIBRA 信号传导在足细胞损伤中的作用
  • 批准号:
    10408806
  • 财政年份:
    2018
  • 资助金额:
    $ 13.14万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了